@FierceMedDev: St. Jude takes to Japan with MRI-safe pacer. Story | Follow @FierceMedDev
@DamianFierce: For CROs big and small, you're only as good as your reputation. The view from DIA 2013. Editor's corner | Follow @DamianFierce
@MichaelGFierce: SEC hammers imaging company, CEO with fraud charges. Report | Follow @MichaelGFierce
> Despite the Supreme Court, Myriad Genetics ($MYGN) is still making money off its BRCA mutation tests, signing a companion diagnostics deal with Tesaro ($TSRO) for a cancer candidate. Article
> Johnson & Johnson ($JNJ) has opened the doors of its Boston Innovation Center, part of a worldwide effort to scout for new deals among early-stage life sciences companies. Story
> In a new study, BioVentrix's Revivent myocardial anchoring system helped heart failure patients sustain 39.6% improvement in heart function after one year. News
> Cepheid ($CPHD) won FDA clearance for its Xpert blood culture test to detect Methicillin-resistant Staphylococcus aureus (MRSA). More
> In new data on Natera's Panorama prenatal screening test, the diagnostic charted an average accuracy of 99.8% in detecting multiple sex chromosome abnormalities. Release
Biotech News
@FierceBiotech: Big Data guru Atul Butte's NuMedii scores $3.5M VC round for 'digital' drug research. FierceBiotech IT story | Follow @FierceBiotech
@JohnCFierce: Stanley Family Foundation spearheads a $21M round for Heptares - (GPCRs). News | Follow @JohnCFierce
@RyanMFierce: J&J's pharma chairman lands 'more deals' in Boston innovation push. Report | Follow @RyanMFierce
> Celgene jumps into blood-cancer race with J&J, adding $818M MorphoSys deal. Report
> Reverse' DNA vaccine bursts into the spotlight with promising Type 1 diabetes data. News
> Genentech eyes 'breakthrough' cancer immunotherapies in pact with U.K. biotech. Story
> U.S. hands out retirement papers to chimps used for research. Article
Pharma News
@FiercePharma: India suspends Actos on safety concerns. Two other (very old) drugs, too. Report | Follow @FiercePharma
@EricPFierce: FDA goes from passive to aggressive on compounders. I wonder how long before certain Congressmen complain. More | Follow @EricPFierce
@CarlyHFierce: Proxy fight heating up at Vivus... First Manhattan announces search for new CEO candidates. Yesterday's story | Follow @CarlyHFierce
> Pfizer, Amgen eye $1B deal for Russian biosimilars developer Biocad. Report
> Novo Nordisk steps away from now-controversial Paula Deen. Article
> Aspen feeds its global appetite with 2nd deal in a week. News
Pharma Manufacturing News
> Aspen, Merck deal includes API plants in U.S., Netherlands. Article
> Roche sets out strict expectations for contractors. Report
> Drugmakers more concerned with quality than price in picking CMOs. Item
> FDA spells out its expectations for crude heparin. More
Vaccines News
> Japan faces vaccine shortage in struggle to control rubella. Report
> ACIP rules on GSK, Novartis and Sanofi vaccines. Story
> Corruption alleged as Indian vaccine shortage continues. Item
> Type 1 diabetes vaccine impresses in early study. News
> Takeda tackling norovirus in bid to grow vaccine biz. Article